Journal article
Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial
Abstract
Overexpression of topoisomerase II protein (topo 2α) is postulated to be more closely associated with responsiveness to anthracycline-containing chemotherapy than human epidermal growth factor receptor type 2 (HER2) gene amplification or alterations in the topoisomerase II alpha gene (TOP2A). The authors used tissue microarrays from 477 of 710 premenopausal women with node-positive breast cancer randomized to CEF or CMF adjuvant chemotherapy in …
Authors
O’Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Huntsman D; Bramwell VH; Andrulis IL; Pritchard KI
Journal
Breast Cancer Research and Treatment, Vol. 128, No. 2,
Publisher
Springer Nature
Publication Date
July 2011
DOI
10.1007/s10549-011-1511-5
ISSN
0167-6806
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAntigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDNA Topoisomerases, Type IIDNA-Binding ProteinsEpirubicinFemaleFluorouracilGene AmplificationHumansImmunoenzyme TechniquesIn Situ Hybridization, FluorescenceMethotrexateMiddle AgedPoly-ADP-Ribose Binding ProteinsRNA, MessengerReceptor, ErbB-2Reverse Transcriptase Polymerase Chain ReactionSurvival RateTreatment Outcome